Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

79.77USD
20 Jun 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$79.77
Open
--
Day's High
--
Day's Low
--
Volume
119
Avg. Vol
2,459,641
52-wk High
$147.13
52-wk Low
$74.14

Latest Key Developments (Source: Significant Developments)

Prothena Announces Global Neuroscience Research & Development Collaboration With Celgene
Tuesday, 20 Mar 2018 04:05pm EDT 

March 20 (Reuters) - Prothena Corporation Plc ::PROTHENA ANNOUNCES GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE FOR NOVEL THERAPIES FOR PATIENTS WITH NEURODEGENERATIVE DISEASES.PROTHENA CORPORATION - PROTHENA TO RECEIVE A $100 MILLION UPFRONT PAYMENT AND A $50 MILLION EQUITY INVESTMENT BY CELGENE.PROTHENA CORPORATION- COLLABORATION INCLUDES POTENTIAL LICENSE PAYMENTS, MILESTONES, PLUS ADDITIONAL ROYALTIES ON SALES FROM LICENSED PROGRAMS FOR CO.PROTHENA CORPORATION PLC - CELGENE WILL SUBSCRIBE TO ABOUT 1.2 MILLION OF PROTHENA'S ORDINARY SHARES AT $42.57 PER SHARE.  Full Article

Beigene Announces Approval Of Revlimid In China
Tuesday, 27 Feb 2018 06:00pm EST 

Feb 27 (Reuters) - Beigene Ltd ::BEIGENE ANNOUNCES APPROVAL OF REVLIMID® FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA.BEIGENE LTD - ‍REVLIMID HAS BEEN APPROVED BY CHINA FOOD AND DRUG ADMINISTRATION FOR TREATMENT OF MULTIPLE MYELOMA​.  Full Article

FDA rejects filing for Celgene MS drug
Tuesday, 27 Feb 2018 04:30pm EST 

Feb 27 (Reuters) - Celgene Corp ::CELGENE PROVIDES REGULATORY UPDATE ON OZANIMOD FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS.CELGENE CORP - ‍FDA DETERMINED NONCLINICAL AND CLINICAL PHARMACOLOGY SECTIONS IN NDA WERE INSUFFICIENT TO PERMIT A COMPLETE REVIEW​.CELGENE - CO INTENDS TO SEEK IMMEDIATE GUIDANCE, INCLUDING REQUESTING A TYPE A MEETING WITH FDA.CELGENE - GOT REFUSAL TO FILE LETTER FROM FDA ABOUT CO'S NDA FOR OZANIMOD IN DEVELOPMENT FOR TREATING PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS.CELGENE - ‍SEEKING GUIDANCE WHICH INCLUDES REQUESTING MEETING WITH FDA, TO ASCERTAIN WHAT ADDITIONAL DATA WILL BE REQUIRED TO RESUBMIT NDA​.  Full Article

Celgene Receives Antitrust Clearance For Juno Acquisition
Wednesday, 21 Feb 2018 07:30am EST 

Feb 21 (Reuters) - Celgene Corp ::CELGENE RECEIVES ANTITRUST CLEARANCE FOR JUNO ACQUISITION.CELGENE CORP - ‍CELGENE EXPECTS JUNO TRANSACTION TO CLOSE IN Q1 OF 2018​.  Full Article

Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients
Thursday, 15 Feb 2018 09:30am EST 

Feb 15 (Reuters) - Celgene Corp ::OTEZLA® (APREMILAST) PHASE II DATA SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS.CELGENE CORP - ‍PHASE III PROGRAM WITH OTEZLA (APREMILAST) IN ULCERATIVE COLITIS EXPECTED TO BEGIN IN 2018​.CELGENE CORP - ‍PRIMARY ENDPOINT OF STUDY WAS TOTAL MAYO SCORE CLINICAL REMISSION AT WEEK 12 FOR 40 MG BID ARM​.  Full Article

Celgene Announces Additional $5 Billion Share Repurchase Authorization
Wednesday, 14 Feb 2018 07:30am EST 

Feb 14 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES ADDITIONAL $5 BILLION SHARE REPURCHASE AUTHORIZATION.CELGENE ANNOUNCES ADDITIONAL $5 BILLION SHARE REPURCHASE AUTHORIZATION.CELGENE CORP - ‍OPEN-ENDED PROGRAM IS EFFECTIVE IMMEDIATELY​.  Full Article

Celgene Prices $4.5 Billion Of Senior Unsecured Notes
Friday, 9 Feb 2018 07:30am EST 

Feb 9 (Reuters) - Celgene Corp ::CELGENE PRICES $4.5 BILLION OF SENIOR UNSECURED NOTES.CELGENE CORP - ANNOUNCED PRICING OF FOUR SERIES OF SENIOR UNSECURED NOTES.CELGENE CORP - NOTES OF $500 MILLION WILL MATURE IN 2021 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 2.875 PERCENT.CELGENE CORP - NOTES OF $1.0 BILLION WILL MATURE IN 2023 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 3.25 PERCENT.CELGENE CORP - NOTES OF $1.5 BILLION WILL MATURE IN 2028 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 3.90 PERCENT.CELGENE CORP - NOTES OF $1.5 BILLION WILL MATURE IN 2048 AND WILL BEAR INTEREST AT AN ANNUAL RATE OF 4.55 PERCENT.CELGENE CORP - 2.875 PERCENT NOTES DUE 2021, 3.25 PERCENT NOTES DUE 2023, 3.90 PERCENT NOTES DUE IN 2028 , 4.55 PERCENT NOTES DUE IN 2048.  Full Article

Celgene Announces Offering Of Senior Unsecured Notes
Thursday, 8 Feb 2018 08:55am EST 

Feb 8 (Reuters) - Celgene Corp ::CELGENE ANNOUNCES OFFERING OF SENIOR UNSECURED NOTES.CELGENE CORP - EXPECTS TO USE NET PROCEEDS FROM OFFERING TO FINANCE A PORTION OF ACQUISITION OF JUNO THERAPEUTICS.  Full Article

Celgene Is In Talks To Buy Juno Therapeutics -WSJ Reporter Tweet‍​
Tuesday, 16 Jan 2018 04:49pm EST 

Jan 16 (Reuters) - :CELGENE IS IN TALKS TO BUY JUNO THERAPEUTICS -WSJ REPORTER TWEET‍​.  Full Article

Celgene CEO Says Plans To Invest Heavily In R&D In 2018
Monday, 8 Jan 2018 10:57am EST 

Jan 8 (Reuters) - Celgene Corp ::CELGENE CEO SAYS PLANS TO INVEST HEAVILY IN RESEARCH AND DEVELOPMENT, BUSINESS DEVELOPMENT IN 2018.CELGENE SAYS HAS 10 LATE STAGE MOLECULES WITH BILLION TO MULTIBILLION-DOLLAR POTENTIAL; COULD ADD MORE THAN $15 BILLION PEAK REVENUE.  Full Article

BRIEF-Evotec And Celgene Enter Into Strategic Oncology Partnership

* DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP